Added to YB: 2026-09-10
Pitch date: 2026-09-07
NVO [neutral]
Novo Nordisk A/S
-2.24%
current return
Author Info
Octopus Value is a private investor focusing on quality companies with margin of safety Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.3T
Pitch Price
DKK 45.58
Price Target
N/A
Dividend
3.91%
EV/EBITDA
8.08
P/E
11.41
EV/Sales
4.30
Sector
Pharmaceuticals
Category
N/A
Novo Nordisk - Q2 2026 Earnings Review
NVO (earnings): Novo Nordisk returned to adjusted sales growth in Q2 and raised 2026 guidance for a second consecutive quarter, but the recovery remains unconvincing. Oral Wegovy’s exceptional launch cannot offset broader GLP-1 weakness: U.S. injectable Wegovy sales fell 22% at CER despite prescription growth. Persistent pricing pressure, slow manufacturing expansion and repeated pipeline setbacks leave limited visibility beyond semaglutide and are prompting reconsideration of the portfolio fit.
Read full article (15 min)